Analyst Reco. Elevation Oncology, Inc.

Equities

ELEV

US28623U1016

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-30 EDT			5-day change	1st Jan Change
3.55 ^USD	-7.79%		-17.82%	+561.08%

04-05	Elevation Oncology, Inc. Announces Management Changes	CI
03-27	Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush Raises Elevation Oncology's PT to $8 From $5, Continues to See 'Intriguing' Opportunity in Shares; Keeps Outperform Rating	03-07	MT
JMP Securities Starts Elevation Oncology' With Market Outperform Rating	03-01	MT
HC Wainwright Adjusts Elevation Oncology Price Target to $6 From $1.50, Maintains Buy Rating	02-20	MT
Wedbush Trims Elevation Oncology's Price Target to $5 From $6, Keeps Outperform Rating	23-08-04	MT
Looming CPI, Fed Rate Decision Drive Quiet Premarket Action for US Equity Futures	23-06-09	MT
Wedbush Lifts Elevation Oncology's Price Target to $6 From $4 on 'Impressive' Data, Keeps Outperform Rating	23-06-05	MT
SVB Securities Upgrades Elevation Oncology to Outperform From Market Perform, Adjusts Price Target to $8 From $5	23-05-30	MT
Wedbush Lowers Elevation Oncology's Price Target to $4 From $6 After Announced Reprioritization of Development Efforts, Keeps Outperform Rating	23-01-23	MT
SVB Securities Cuts Price Target on Elevation Oncology to $1 From $2, Maintains Market Perform Rating	23-01-09	MT
JPMorgan Downgrades Elevation Oncology to Underweight From Neutral	22-11-10	MT
SVB Securities Downgrades Elevation Oncology to Market Perform From Outperform, Adjusts Price Target to $2 From $11	22-11-07	MT
Wedbush Lowers Elevation Oncology's Price Target to $6 From $8, Updates Expectations Around Future Equity Raises; Keeps Outperform Rating	22-11-04	MT
HC Wainwright Assumes Elevation Oncology at Buy with $7.50 Price Target	22-09-19	MT
JPMorgan Downgrades Elevation Oncology to Neutral from Overweight	22-08-08	MT
Wedbush Adjusts Price Target on Elevation Oncology to $8 From $15; Outperform Rating Kept	22-07-29	MT
Wedbush Adjusts Elevation Oncology's Price Target to $15 From $21, Keeps Outperform Rating	22-05-06	MT
Wedbush Cuts Elevation Oncology's Price Target to $21 From $27, Citing 'Financing Environment;' Outperform Rating Kept	22-03-04	MT
HC Wainwright Initiates Coverage on Elevation Oncology With Buy Rating, $12 Price Target	21-12-23	MT
ELEVATION ONCOLOGY : JPMorgan Starts Elevation Oncology at Overweight with $24 Price Target	21-07-20	MT
ELEVATION ONCOLOGY : SVB Leerink Starts Elevation Oncology at Outperform With $20 Price Target	21-07-20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Elevation Oncology, Inc.

Equities

ELEV

US28623U1016

Analyst Reco.

Filters